How I manage acute lymphoblastic leukemia in fanconi anemia?

doi:10.15406/jbmoa.2018.06.00223

Journal of

eISSN: 2469 - 2786

Bacteriology & Mycology: Open Access

Opinion Volume 6 Issue 5

How I manage acute lymphoblastic leukemia in fanconi anemia?

Ahmed Ibrahim Jessim,¹

Verify Captcha

Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.

Abdolkarimi Babak¹

¹Department of pediatrics, Lorestan University of Medical Sciences, Iran
²Associate professor of Pediatric Hematology/Oncology, Shiraz University of Medical Sciences, Iran

Correspondence: Ahmed Ibrahim Jessim, Ministry of Science and Technology. Directorate of Treatment and disposal of chemical, biological and military hazardous wastes, Center for research and evaluation, Iraq, Tel 9.64771E+12

Received: October 20, 2018 | Published: October 31, 2018

Citation: Babak A, Mahdi S. How I manage acute lymphoblastic leukemia in fanconi anemia? J Bacteriol Mycol Open Access. 2018;6(5):303-304. DOI: 10.15406/jbmoa.2018.06.00223

Download PDF

Introduction

Fanconi anemia (FA) is a genomic instability situation characterized by a wide array of congenital anomalities, bone marrow failure, leads to malignancy. The cumulative incidence of leukemia in Fanconi anemia is about 10% until first 25 years of age, and the cumulative incidence of any hematological dyscrasia is up to 90%. In this disorder 94% of leukemias are myeloid as compared to 84% of leukemia’s being lymphoid in non-Fanconic patients.¹This association suggests that FA is a preleukemic condition for acute myeloid leukemia (AML). Acute lymphoblastic leukemia (ALL) has also rarely been reported.

Body of article

Because of their rarity, there is no consensus on how to treat Acute Lymphoblastic leukemias when they develop. Reports of immune function in this population are limited but, these patients have a degree of primary immunodeficiency; absolute numbers of B cells and natural killer (NK) cells were reduced compared to controls, while absolute number of T cells were reported to be within normal range.² Perforin and enzyme content of NK cells was reduced along with the NK cell cytotoxicity. Proliferation in response to tetanus was decreased while responses to phytohemagglutinin and candida were not. Cytotoxic T cell function was also reduced. Immunoglobulin G levels were normal in those who were evaluated.³ Antibiotic chemoprophylaxis has a major complementary role in patients with persistent infections despite “optimal” immunoglobulin replacement (residual IgG concentration>8g/L), with same modalities as in agammaglobulinemia.⁴ So, co-administration of IVIG 0.4gr/kg with antibiotic and antifungal prophylaxis for primary immune deficiency disorders; cotrimoxazole for cellular immune deficiency at start of chemotherapy regimen is suggested.³ If FA patient live in developing countries and has probable malnutrition WHO guidelines for the management of children with severe acute malnutrition are also recommended.

Box 1: If the child has no complication,: cotrimoxazole for 5 days (20mg of sulfamethoxazole + 4mg of trimethoprim per kilogram orally twice daily) is prescribed. If child has complication: ampicillin (25-50mg/kg IM/IV 6-hourly for 2days), then oral amoxicillin (15mg/kg 8-hourly for 5days) OR, if amoxicillin is not available, oral Ampicillin (25-50mg/kg 6-hourly for 5days) over a total of 7days and Gentamicin (7.5mg/kg IM /IV) once daily for 7days are prescribed. If the child hasn’t improvement within 48 hours: chloramphenicol (25mg/kg IM/IV 8-hourly) for 5days adds to this regimen. If other specific infections are identified (such as pneumonia, dysentery, skin or soft tissue infections): give antibiotics as appropriate. Antibiotics should be continued for at least 5 days. The duration of treatment depends on the response and nutritional status of the child. If anorexia persists after 5 days of treatment, give the child another 5-day course. The regimen should be adapted based on local resistance patterns.⁴ It seems FA induced acute leukemia classification as High risk or standard risk in ALL or cytogenetic based risk stratification in AML are defeasible. FA patients should be transplanted finally, but they have chromosomal breakage constitutionally, therefore in these cases modified chemotherapy dosing with removal of DNA cross-linking agents (Cyclophosphamide) are suggested; in order to reach sustain bone marrow remission and decrease chemotherapy-related toxicities. The majority of FA patients involved by acute leukemia were treated by classic chemotherapy protocols had been died.^1,5,6 Therefore choosing treatment protocols based on routine classification should be avoided. The oncologists should suffice to non-myelosuppresive agents such as steroids, Vincristin, Asparginase in ALL patients. Children oncology group (COG) has chemotherapy regimen for lesser risk ALL⁷ include:

Induction phase:

Vincristine 1.5mg/m² IV on days 1, 8, 15 , 22
Prednisone 40mg/m² in on days 1 to 28 divides 3 doses then taper in one week
L-asparaginase 6,000units/m² IM on days 2, 5, 8, 12, 15 and 19
Intrathecal MTX on days 1 , 22

Additional doses are given on days 8 and 15 when CNS status is present. In AML patients administration of routine chemotherapy protocols such as MRC12, BFM-98 include DNA cross-linking agents (Ara-C and Etoposide and antracyclines) is fatal for FA patients.⁸ Traditional sight for decreasing 50% dose adjustment for these agents is unpromising. It seems that medications such as reduced dose Cytarabin should be limited to preparation for allogenic BMT if full matched donor exists. In this pre-transplant stage some modified regimens are administered such as Mini-FLAG include: Fludarabine 30mg/m² and Ara-C 300mg/m² each on days 2-4 and granulocyte-colony stimulating factor (G-CSF) 5mcg/kg is Days 1-5 may be recommended.⁹ If full matched donor doesn’t exist administration of metronomic chemotherapy with oral antimetabolic agents(6-Meraptopurine, 6-Thioguanine) are recommended similar to elderly patients(>65years) involved by AML .In these patients there is chromosomal breakage due to aging similar to FA patients. Therefore treatment approach in FA patients with AML is similar to elderly patients involved by AML. These patients treatment with daily oral 6-mercaptopurine 75mg/ m² similar to patients with age >60 years, non-promyelocytic AML, the absence of uncontrolled comorbidities, and patient not amenable to curative treatment is suggested.¹⁰Every time that the blast cells increases repeating Mini-FLAG regimen is suggested. Also, administration of intravenous amino-transfusion, micronutrients and non-B-vitamins including calcium, vitamins A, D, C and E, fatty acids, selenium, and zinc during chemotherapy courses are useful.¹¹

Conclusion

Because ALL patients with FA are rare, controversial topics about treatment of these patients are many .We need to many clinical trials to introduce safe and effective chemotherapy regimen which hasn’t been mortality before bone marrow transplantation.